James C Murray

Re-Vana Therapeutics Ltd. is a specialty ocular therapeutic and British drug delivery company that focuses on developing its internal pipeline and external strategic collaborations to advance its novel drug delivery platform. In 2022, Re-Vana won the Ophthalmic Innovation Summit Retina Award in drug delivery and the Belfast Nth Ireland Chamber 2022 Award for Business Innovation. Re-Vana Therapeutics was founded in 2016 as a spin-out from Queen's University, with the main office located in Belfast, UK, and an office, Re-Vana Therapeutics, Inc., based elsewhere. The company has raised more than $17.75m to support the development of sustained release biologics. In 2019, Re-Vana secured funding from Innovate totaling more than $400k to support the development of a sustained release drug. Additionally, in 2020, the company entered into a strategic feasibility collaboration with a leading pharmaceutical company for a novel therapeutic.

Nectar Services Corp. engages in the development of proactive network monitoring and management software for the unified communications industry. Its products include UC management platform, UC diagnostics, perspective, US foundation and call analysis. The firm also provides consulting, implementation, training and technical support services. The company was founded by David Giangano and Frances Vinci in 2006 and is headquartered in Jericho, NY.

Nectar Services Corp. engages in the development of proactive network monitoring and management software for the unified communications industry. Its products include UC management platform, UC diagnostics, perspective, US foundation and call analysis. The firm also provides consulting, implementation, training and technical support services. The company was founded by David Giangano and Frances Vinci in 2006 and is headquartered in Jericho, NY.

Nectar Services Corp. engages in the development of proactive network monitoring and management software for the unified communications industry. Its products include UC management platform, UC diagnostics, perspective, US foundation and call analysis. The firm also provides consulting, implementation, training and technical support services. The company was founded by David Giangano and Frances Vinci in 2006 and is headquartered in Jericho, NY.

Nectar Services Corp. engages in the development of proactive network monitoring and management software for the unified communications industry. Its products include UC management platform, UC diagnostics, perspective, US foundation and call analysis. The firm also provides consulting, implementation, training and technical support services. The company was founded by David Giangano and Frances Vinci in 2006 and is headquartered in Jericho, NY.

Nectar Services Corp. engages in the development of proactive network monitoring and management software for the unified communications industry. Its products include UC management platform, UC diagnostics, perspective, US foundation and call analysis. The firm also provides consulting, implementation, training and technical support services. The company was founded by David Giangano and Frances Vinci in 2006 and is headquartered in Jericho, NY.

Re-Vana Therapeutics Ltd. is a specialty ocular therapeutic and British drug delivery company that focuses on developing its internal pipeline and external strategic collaborations to advance its novel drug delivery platform. In 2022, Re-Vana won the Ophthalmic Innovation Summit Retina Award in drug delivery and the Belfast Nth Ireland Chamber 2022 Award for Business Innovation. Re-Vana Therapeutics was founded in 2016 as a spin-out from Queen's University, with the main office located in Belfast, UK, and an office, Re-Vana Therapeutics, Inc., based elsewhere. The company has raised more than $17.75m to support the development of sustained release biologics. In 2019, Re-Vana secured funding from Innovate totaling more than $400k to support the development of a sustained release drug. Additionally, in 2020, the company entered into a strategic feasibility collaboration with a leading pharmaceutical company for a novel therapeutic.

ExSight Venture Management LLC is a venture capital firm founded in 2014 by James C. Murray. The firm is headquartered in New York.

Re-Vana Therapeutics Ltd. is a specialty ocular therapeutic and British drug delivery company that focuses on developing its internal pipeline and external strategic collaborations to advance its novel drug delivery platform. In 2022, Re-Vana won the Ophthalmic Innovation Summit Retina Award in drug delivery and the Belfast Nth Ireland Chamber 2022 Award for Business Innovation. Re-Vana Therapeutics was founded in 2016 as a spin-out from Queen's University, with the main office located in Belfast, UK, and an office, Re-Vana Therapeutics, Inc., based elsewhere. The company has raised more than $17.75m to support the development of sustained release biologics. In 2019, Re-Vana secured funding from Innovate totaling more than $400k to support the development of a sustained release drug. Additionally, in 2020, the company entered into a strategic feasibility collaboration with a leading pharmaceutical company for a novel therapeutic.

ExSight Venture Management LLC is a venture capital firm founded in 2014 by James C. Murray. The firm is headquartered in New York.